Q1 2026 Embla Medical hf Earnings Call Transcript
Key Points
- Embla Medical hf (OSSUY) reported a 15% increase in sales for Q1 2026, with 4% organic growth.
- Strong performance in prosthetics and neuro-orthotics, with 9% organic growth driven by innovations in Bionics and Feet products.
- The ForMotion brand rollout in Patient Care is over 90% complete, expected to enhance long-term growth and profitability.
- APAC region showed robust sales growth with 14% organic growth across all segments.
- Net profit grew by 21%, driven by growing operating results and favorable changes in net financial expenses.
- EBITDA margin decreased by 1 percentage point to 17% due to external factors like FX and tariffs.
- Sales in the Bracing and Supports segment grew only 1%, with flat growth in the Americas due to competitive pressures.
- Patient Care sales declined by 1% in Europe, affected by timing effects and holiday overlaps.
- Gross profit margin decreased slightly from 63% to 62% compared to Q1 2025, impacted by FX and tariffs.
- Free cash flow generation was lower than the previous year, mainly due to timing effects in net working capital.
Welcome to Embla Medical Q1 2026 conference call. Today's call is being recorded. If you have any objections to this, please disconnect your line.
(Operator Instructions)
I would like to introduce President and CEO, Sveinn Sölvason, and CFO, Arna Sveinsdóttir.
Sveinn, please begin.
¶ -
Thank you very much.
Good morning, and welcome to the Embla medical conference call, where we will review the first quarter results for 2026. I'm Sveinn Sölvason, President and CEO of Embla Medical.
And joining me on today's call is our Chief Financial Officer, Arna Sveinsdóttir; and Embla Medical's Head of Investor Relations Klaus Sindahl.
The presentation should take approximately 15 minutes, after which there will be an opportunity to ask questions, during a Q&A session.
Now, if you would please go to the next slide.
We are seeing good progress at the beginning of 2026. Sales in the first quarter amounted to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
